CA1187791A - Insoluble crosslinked cytotoxic oxidase-peroxidase system - Google Patents
Insoluble crosslinked cytotoxic oxidase-peroxidase systemInfo
- Publication number
- CA1187791A CA1187791A CA000400618A CA400618A CA1187791A CA 1187791 A CA1187791 A CA 1187791A CA 000400618 A CA000400618 A CA 000400618A CA 400618 A CA400618 A CA 400618A CA 1187791 A CA1187791 A CA 1187791A
- Authority
- CA
- Canada
- Prior art keywords
- matter
- composition
- prepared according
- enzyme
- set forth
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 230000001472 cytotoxic effect Effects 0.000 title claims abstract description 25
- 231100000433 cytotoxic Toxicity 0.000 title abstract description 9
- 238000000034 method Methods 0.000 claims abstract description 80
- 230000008569 process Effects 0.000 claims abstract description 77
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 76
- 102000004190 Enzymes Human genes 0.000 claims abstract description 53
- 108090000790 Enzymes Proteins 0.000 claims abstract description 53
- 229940088598 enzyme Drugs 0.000 claims abstract description 53
- 230000000694 effects Effects 0.000 claims abstract description 23
- 102000003992 Peroxidases Human genes 0.000 claims abstract description 22
- 210000000987 immune system Anatomy 0.000 claims abstract description 8
- 108010015776 Glucose oxidase Proteins 0.000 claims abstract description 7
- 239000004366 Glucose oxidase Substances 0.000 claims abstract description 7
- 229940116332 glucose oxidase Drugs 0.000 claims abstract description 7
- 235000019420 glucose oxidase Nutrition 0.000 claims abstract description 7
- 108010088751 Albumins Proteins 0.000 claims abstract 3
- 102000009027 Albumins Human genes 0.000 claims abstract 3
- 239000000203 mixture Substances 0.000 claims description 54
- 210000004027 cell Anatomy 0.000 claims description 29
- 239000000243 solution Substances 0.000 claims description 24
- 102000004169 proteins and genes Human genes 0.000 claims description 21
- 108090000623 proteins and genes Proteins 0.000 claims description 21
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 claims description 18
- 108040007629 peroxidase activity proteins Proteins 0.000 claims description 17
- 108010001336 Horseradish Peroxidase Proteins 0.000 claims description 12
- 108700020962 Peroxidase Proteins 0.000 claims description 10
- 102000003896 Myeloperoxidases Human genes 0.000 claims description 9
- 108090000235 Myeloperoxidases Proteins 0.000 claims description 9
- 210000003527 eukaryotic cell Anatomy 0.000 claims description 9
- 210000001236 prokaryotic cell Anatomy 0.000 claims description 9
- 102000004316 Oxidoreductases Human genes 0.000 claims description 8
- 108090000854 Oxidoreductases Proteins 0.000 claims description 8
- 239000003795 chemical substances by application Substances 0.000 claims description 8
- 210000004881 tumor cell Anatomy 0.000 claims description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 8
- 238000004519 manufacturing process Methods 0.000 claims description 7
- 108010023244 Lactoperoxidase Proteins 0.000 claims description 5
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 claims description 5
- 229940057428 lactoperoxidase Drugs 0.000 claims description 5
- 238000001035 drying Methods 0.000 claims description 4
- -1 halide ion Chemical class 0.000 claims description 4
- 108091003079 Bovine Serum Albumin Proteins 0.000 claims description 3
- 108091006905 Human Serum Albumin Proteins 0.000 claims description 3
- 102000008100 Human Serum Albumin Human genes 0.000 claims description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 3
- 229940098773 bovine serum albumin Drugs 0.000 claims description 3
- 210000005170 neoplastic cell Anatomy 0.000 claims description 3
- 230000004936 stimulating effect Effects 0.000 claims description 3
- 239000000470 constituent Substances 0.000 claims description 2
- 230000000379 polymerizing effect Effects 0.000 claims 8
- 239000007853 buffer solution Substances 0.000 claims 7
- 102000013415 peroxidase activity proteins Human genes 0.000 claims 6
- 239000002195 soluble material Substances 0.000 claims 6
- 230000001461 cytolytic effect Effects 0.000 claims 5
- 102000045576 Lactoperoxidases Human genes 0.000 claims 4
- 238000001816 cooling Methods 0.000 claims 3
- 239000007788 liquid Substances 0.000 claims 3
- 241000270295 Serpentes Species 0.000 claims 2
- 238000004132 cross linking Methods 0.000 claims 2
- 230000003013 cytotoxicity Effects 0.000 claims 2
- 231100000135 cytotoxicity Toxicity 0.000 claims 2
- 238000002791 soaking Methods 0.000 claims 2
- 206010057248 Cell death Diseases 0.000 claims 1
- 108010093894 Xanthine oxidase Proteins 0.000 claims 1
- 102100033220 Xanthine oxidase Human genes 0.000 claims 1
- 230000009089 cytolysis Effects 0.000 claims 1
- 238000001914 filtration Methods 0.000 claims 1
- 238000007710 freezing Methods 0.000 claims 1
- 230000008014 freezing Effects 0.000 claims 1
- 238000000227 grinding Methods 0.000 claims 1
- 238000002156 mixing Methods 0.000 claims 1
- 229920000642 polymer Polymers 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
- 241000700159 Rattus Species 0.000 abstract description 45
- 238000002360 preparation method Methods 0.000 abstract description 15
- 230000004614 tumor growth Effects 0.000 abstract description 10
- 230000028993 immune response Effects 0.000 abstract description 9
- 208000010454 Experimental Liver Neoplasms Diseases 0.000 abstract description 7
- 108010093096 Immobilized Enzymes Proteins 0.000 abstract description 5
- 241000699670 Mus sp. Species 0.000 abstract description 5
- 239000007924 injection Substances 0.000 abstract description 5
- 238000002347 injection Methods 0.000 abstract description 5
- 239000002245 particle Substances 0.000 abstract description 5
- 241000124008 Mammalia Species 0.000 abstract description 4
- 230000009471 action Effects 0.000 abstract description 4
- 230000000638 stimulation Effects 0.000 abstract description 4
- 208000035473 Communicable disease Diseases 0.000 abstract description 3
- 230000006378 damage Effects 0.000 abstract description 3
- 238000002513 implantation Methods 0.000 abstract description 3
- 201000001441 melanoma Diseases 0.000 abstract description 3
- 201000010099 disease Diseases 0.000 abstract description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 2
- 238000000338 in vitro Methods 0.000 abstract description 2
- 230000009826 neoplastic cell growth Effects 0.000 abstract description 2
- 230000000844 anti-bacterial effect Effects 0.000 abstract 1
- 108010046301 glucose peroxidase Proteins 0.000 abstract 1
- 239000007928 intraperitoneal injection Substances 0.000 abstract 1
- 239000000758 substrate Substances 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 230000005909 tumor killing Effects 0.000 abstract 1
- 241001465754 Metazoa Species 0.000 description 33
- 238000011282 treatment Methods 0.000 description 23
- 210000001519 tissue Anatomy 0.000 description 17
- 239000003112 inhibitor Substances 0.000 description 9
- 239000003226 mitogen Substances 0.000 description 8
- 230000003389 potentiating effect Effects 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 7
- 230000004044 response Effects 0.000 description 7
- 210000004989 spleen cell Anatomy 0.000 description 7
- POGSZHUEECCEAP-ZETCQYMHSA-N (2s)-2-amino-3-(3-amino-4-hydroxyphenyl)propanoic acid Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(N)=C1 POGSZHUEECCEAP-ZETCQYMHSA-N 0.000 description 6
- 108010062580 Concanavalin A Proteins 0.000 description 6
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 6
- 239000008103 glucose Substances 0.000 description 6
- 239000000427 antigen Substances 0.000 description 5
- 102000036639 antigens Human genes 0.000 description 5
- 108091007433 antigens Proteins 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 206010025323 Lymphomas Diseases 0.000 description 4
- 210000000683 abdominal cavity Anatomy 0.000 description 4
- 239000006285 cell suspension Substances 0.000 description 4
- 210000002540 macrophage Anatomy 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 206010003445 Ascites Diseases 0.000 description 3
- 206010028851 Necrosis Diseases 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 208000009956 adenocarcinoma Diseases 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 229910052739 hydrogen Inorganic materials 0.000 description 3
- 239000001257 hydrogen Substances 0.000 description 3
- 230000017074 necrotic cell death Effects 0.000 description 3
- 230000001613 neoplastic effect Effects 0.000 description 3
- XJPHGGXFBWOHFL-QMMMGPOBSA-N (2s)-2-hydrazinyl-3-(4-hydroxyphenyl)propanoic acid Chemical compound NN[C@H](C(O)=O)CC1=CC=C(O)C=C1 XJPHGGXFBWOHFL-QMMMGPOBSA-N 0.000 description 2
- IQFYYKKMVGJFEH-OFKYTIFKSA-N 1-[(2r,4s,5r)-4-hydroxy-5-(tritiooxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound C1[C@H](O)[C@@H](CO[3H])O[C@H]1N1C(=O)NC(=O)C(C)=C1 IQFYYKKMVGJFEH-OFKYTIFKSA-N 0.000 description 2
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 206010039491 Sarcoma Diseases 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- FOCVUCIESVLUNU-UHFFFAOYSA-N Thiotepa Chemical compound C1CN1P(N1CC1)(=S)N1CC1 FOCVUCIESVLUNU-UHFFFAOYSA-N 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 239000012736 aqueous medium Substances 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000003416 augmentation Effects 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 210000002808 connective tissue Anatomy 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 239000003018 immunosuppressive agent Substances 0.000 description 2
- 210000001165 lymph node Anatomy 0.000 description 2
- 230000003211 malignant effect Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 210000000822 natural killer cell Anatomy 0.000 description 2
- 150000002978 peroxides Chemical class 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 230000002269 spontaneous effect Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 229960001196 thiotepa Drugs 0.000 description 2
- HHLJUSLZGFYWKW-UHFFFAOYSA-N triethanolamine hydrochloride Chemical compound Cl.OCCN(CCO)CCO HHLJUSLZGFYWKW-UHFFFAOYSA-N 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- 208000006678 Abdominal Neoplasms Diseases 0.000 description 1
- 206010001233 Adenoma benign Diseases 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 240000003291 Armoracia rusticana Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 241001315286 Damon Species 0.000 description 1
- 208000007659 Fibroadenoma Diseases 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 108010015133 Galactose oxidase Proteins 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 239000012981 Hank's balanced salt solution Substances 0.000 description 1
- 208000017604 Hodgkin disease Diseases 0.000 description 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
- 102100038609 Lactoperoxidase Human genes 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- PPQNQXQZIWHJRB-UHFFFAOYSA-N Methylcholanthrene Chemical compound C1=CC=C2C3=CC4=CC=C(C)C(CC5)=C4C5=C3C=CC2=C1 PPQNQXQZIWHJRB-UHFFFAOYSA-N 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241001467552 Mycobacterium bovis BCG Species 0.000 description 1
- 241000204031 Mycoplasma Species 0.000 description 1
- 108010007843 NADH oxidase Proteins 0.000 description 1
- 108010002998 NADPH Oxidases Proteins 0.000 description 1
- 102000004722 NADPH Oxidases Human genes 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- MASVCBBIUQRUKL-UHFFFAOYSA-N POPOP Chemical compound C=1N=C(C=2C=CC(=CC=2)C=2OC(=CN=2)C=2C=CC=CC=2)OC=1C1=CC=CC=C1 MASVCBBIUQRUKL-UHFFFAOYSA-N 0.000 description 1
- 241000237988 Patellidae Species 0.000 description 1
- 240000002825 Solanum vestissimum Species 0.000 description 1
- 235000018259 Solanum vestissimum Nutrition 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 206010054094 Tumour necrosis Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 240000006365 Vitis vinifera Species 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 239000012062 aqueous buffer Substances 0.000 description 1
- OHDRQQURAXLVGJ-HLVWOLMTSA-N azane;(2e)-3-ethyl-2-[(e)-(3-ethyl-6-sulfo-1,3-benzothiazol-2-ylidene)hydrazinylidene]-1,3-benzothiazole-6-sulfonic acid Chemical compound [NH4+].[NH4+].S/1C2=CC(S([O-])(=O)=O)=CC=C2N(CC)C\1=N/N=C1/SC2=CC(S([O-])(=O)=O)=CC=C2N1CC OHDRQQURAXLVGJ-HLVWOLMTSA-N 0.000 description 1
- 229960000190 bacillus calmette–guérin vaccine Drugs 0.000 description 1
- 238000007630 basic procedure Methods 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 201000008275 breast carcinoma Diseases 0.000 description 1
- 201000003149 breast fibroadenoma Diseases 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 229940000425 combination drug Drugs 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- MHUWZNTUIIFHAS-CLFAGFIQSA-N dioleoyl phosphatidic acid Chemical class CCCCCCCC\C=C/CCCCCCCC(=O)OCC(COP(O)(O)=O)OC(=O)CCCCCCC\C=C/CCCCCCCC MHUWZNTUIIFHAS-CLFAGFIQSA-N 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000001493 electron microscopy Methods 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 230000003328 fibroblastic effect Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000003365 glass fiber Substances 0.000 description 1
- 210000000224 granular leucocyte Anatomy 0.000 description 1
- 230000003100 immobilizing effect Effects 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 230000001861 immunosuppressant effect Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 230000000394 mitotic effect Effects 0.000 description 1
- 239000004570 mortar (masonry) Substances 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 210000002747 omentum Anatomy 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000004783 oxidative metabolism Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 210000003200 peritoneal cavity Anatomy 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 210000000717 sertoli cell Anatomy 0.000 description 1
- 208000018655 severe necrosis Diseases 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 230000021595 spermatogenesis Effects 0.000 description 1
- 238000013223 sprague-dawley female rat Methods 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 230000005748 tumor development Effects 0.000 description 1
- 230000002476 tumorcidal effect Effects 0.000 description 1
- 208000010576 undifferentiated carcinoma Diseases 0.000 description 1
- 210000005166 vasculature Anatomy 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 229940075420 xanthine Drugs 0.000 description 1
- NWONKYPBYAMBJT-UHFFFAOYSA-L zinc sulfate Chemical compound [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/44—Oxidoreductases (1)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/38—Albumins
- A61K38/385—Serum albumin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/44—Oxidoreductases (1)
- A61K38/443—Oxidoreductases (1) acting on CH-OH groups as donors, e.g. glucose oxidase, lactate dehydrogenase (1.1)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N11/00—Carrier-bound or immobilised enzymes; Carrier-bound or immobilised microbial cells; Preparation thereof
- C12N11/18—Multi-enzyme systems
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y101/00—Oxidoreductases acting on the CH-OH group of donors (1.1)
- C12Y101/03—Oxidoreductases acting on the CH-OH group of donors (1.1) with a oxygen as acceptor (1.1.3)
- C12Y101/03004—Glucose oxidase (1.1.3.4)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y111/00—Oxidoreductases acting on a peroxide as acceptor (1.11)
- C12Y111/01—Peroxidases (1.11.1)
- C12Y111/01007—Peroxidase (1.11.1.7), i.e. horseradish-peroxidase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Dermatology (AREA)
- Inorganic Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US06/251,694 US4486408A (en) | 1981-04-07 | 1981-04-07 | Insoluble crosslinked cytotoxic oxidase-peroxidase system |
| US251,694 | 1981-04-07 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA1187791A true CA1187791A (en) | 1985-05-28 |
Family
ID=22953019
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA000400618A Expired CA1187791A (en) | 1981-04-07 | 1982-04-07 | Insoluble crosslinked cytotoxic oxidase-peroxidase system |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US4486408A (en:Method) |
| EP (1) | EP0062434B1 (en:Method) |
| JP (1) | JPS57177694A (en:Method) |
| AR (1) | AR229260A1 (en:Method) |
| AT (1) | ATE15813T1 (en:Method) |
| AU (1) | AU556620B2 (en:Method) |
| CA (1) | CA1187791A (en:Method) |
| DE (1) | DE3266476D1 (en:Method) |
| DK (1) | DK155082A (en:Method) |
| IL (1) | IL65382A (en:Method) |
| IN (1) | IN156471B (en:Method) |
| NO (1) | NO158004C (en:Method) |
| ZA (1) | ZA821924B (en:Method) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0236610A1 (en) * | 1986-03-13 | 1987-09-16 | Laclede Professional Products, Inc. | Enzymatic bandages and pads |
| US4576817A (en) * | 1984-06-07 | 1986-03-18 | Laclede Professional Products, Inc. | Enzymatic bandages and pads |
| SE8500341L (sv) * | 1985-01-24 | 1986-07-25 | Pharmacia Ab | Desinfektionssats samt sett for desinfektion |
| US4974929A (en) * | 1987-09-22 | 1990-12-04 | Baxter International, Inc. | Fiber optical probe connector for physiologic measurement devices |
| AU4402589A (en) * | 1988-09-28 | 1990-04-18 | Ideon Corporation | Combination enzyme immunotherapeutics |
| FR2646777B1 (fr) * | 1989-05-12 | 1993-09-03 | Bio Serae Lab | Procede de preparation d'un produit particulaire antimicrobien, produit antimicrobien obtenu et applications |
| US5486360A (en) * | 1993-04-22 | 1996-01-23 | St. Joseph Health Centre | Method of treating tumour cells using catalase |
| CA2150029A1 (en) * | 1993-09-22 | 1995-03-30 | Spencer H. Lin | Immobilization of chemically cross-linked proteins on solid supports |
| US7192766B2 (en) * | 2001-10-23 | 2007-03-20 | Medtronic Minimed, Inc. | Sensor containing molded solidified protein |
| WO2013006762A2 (en) * | 2011-07-06 | 2013-01-10 | The Regents Of The University Of California | Multiple-enzyme nanocomplexes |
| KR20250004257A (ko) * | 2022-04-13 | 2025-01-07 | 엑스옥세미스 인코퍼레이티드 | 고형 암을 치료하기 위한 조성물 및 방법 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4004979A (en) * | 1968-03-29 | 1977-01-25 | Agence Nationale De Valorisation De La Recherche (Anvar) | Preparation of active proteins cross-linked to inactive proteins |
| US4178362A (en) * | 1969-06-03 | 1979-12-11 | Telec S.A. | Enzymatic dentifrices |
| US3638558A (en) * | 1970-03-26 | 1972-02-01 | Burger King Corp | Cooking apparatus for comestibles immersed in heated oil |
| JPS528795B2 (en:Method) * | 1971-12-30 | 1977-03-11 | ||
| DE2214442C3 (de) * | 1972-03-24 | 1981-09-10 | Boehringer Mannheim Gmbh, 6800 Mannheim | Verfahren zur Überführung von Glucose in Gluconsäure |
| DE2307904A1 (de) * | 1973-02-17 | 1974-08-29 | Hoechst Ag | Verwendung von katalasefreien oder katalsearmen glucoseoxidase-praeparaten als zytostatikum fuer maligne zellen |
| DK146942C (da) * | 1978-04-19 | 1984-07-30 | Novo Industri As | Fremgangsmaade til fremstilling af et immobiliseret enzymprodukt |
| DE2911192A1 (de) * | 1979-03-22 | 1980-10-02 | Boehringer Sohn Ingelheim | Neuartiges immobilisiertes glucoseoxidase-katalasepraeparat und seine verwendung zur enzymatischen glucoseoxidation |
-
1981
- 1981-04-07 US US06/251,694 patent/US4486408A/en not_active Expired - Fee Related
-
1982
- 1982-03-19 AT AT82301451T patent/ATE15813T1/de not_active IP Right Cessation
- 1982-03-19 DE DE8282301451T patent/DE3266476D1/de not_active Expired
- 1982-03-19 EP EP82301451A patent/EP0062434B1/en not_active Expired
- 1982-03-19 AU AU81739/82A patent/AU556620B2/en not_active Ceased
- 1982-03-22 ZA ZA821924A patent/ZA821924B/xx unknown
- 1982-03-30 IL IL65382A patent/IL65382A/xx unknown
- 1982-03-31 IN IN360/CAL/82A patent/IN156471B/en unknown
- 1982-04-05 DK DK155082A patent/DK155082A/da not_active IP Right Cessation
- 1982-04-05 AR AR289004A patent/AR229260A1/es active
- 1982-04-06 NO NO821167A patent/NO158004C/no unknown
- 1982-04-07 CA CA000400618A patent/CA1187791A/en not_active Expired
- 1982-04-07 JP JP57057947A patent/JPS57177694A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| ZA821924B (en) | 1983-04-27 |
| EP0062434B1 (en) | 1985-09-25 |
| NO158004B (no) | 1988-03-21 |
| AR229260A1 (es) | 1983-07-15 |
| AU556620B2 (en) | 1986-11-13 |
| NO821167L (no) | 1982-10-08 |
| DK155082A (da) | 1982-10-08 |
| NO158004C (no) | 1988-06-29 |
| DE3266476D1 (en) | 1985-10-31 |
| IN156471B (en:Method) | 1985-08-10 |
| AU8173982A (en) | 1982-10-14 |
| IL65382A0 (en) | 1982-05-31 |
| US4486408A (en) | 1984-12-04 |
| JPS57177694A (en) | 1982-11-01 |
| ATE15813T1 (de) | 1985-10-15 |
| IL65382A (en) | 1986-04-29 |
| EP0062434A1 (en) | 1982-10-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Barnes | The enzymes of lymphocytes and polymorphonuclear leucocytes | |
| Gelbard et al. | Collagenase for Peyronie's disease experimental studies | |
| Simpson et al. | Insulin receptor phosphorylation may not be a prerequisite for acute insulin action | |
| US6056955A (en) | Topical treatment of streptococcal infections | |
| CA1187791A (en) | Insoluble crosslinked cytotoxic oxidase-peroxidase system | |
| US4870002A (en) | Method of prevention of oxidative injury to cells | |
| JPH08507677A (ja) | 糖脂質酵素−ポリマー結合体 | |
| JPH10508205A (ja) | 肝細胞および膵臓ランゲルハンス島細胞を単離するためのコラーゲナーゼおよびキモパパインを含有する組成物 | |
| Sylvén et al. | Studies on the histochemical “leucine aminopeptidase” reaction: IV. Chemical and histochemical characterization of the intracellular and stromal LNA reactions in solid tumor transplants | |
| Monte et al. | Inhibition of lymphocyte-induced angiogenesis by free radical scavengers | |
| Ginsburg | Action of streptococcal haemolysins and proteolytic enzymes on Ehrlich ascites tumour cells | |
| US4330527A (en) | Wound treatment agent | |
| JP3140797B2 (ja) | 安定化コンドロイチナーゼａｂｃ、その保存方法及び治療剤 | |
| Schwartz et al. | Actinomycin D: effects on Ridgway osteogenic sarcoma in mice | |
| IE52794B1 (en) | Insoluble crosslinked cytotoxic oxidase-peroxidase system | |
| EP0988374B1 (en) | Hydrophilic composition containing protease produced by vibrio proteolyticus | |
| Schuster et al. | Toxic properties of the cell wall of gram-positive bacteria | |
| US4766150A (en) | Method for immunosuppression | |
| JPH04305533A (ja) | 生医学的用途におけるオキシラジカル損傷を減少させる組成物及び方法 | |
| JP3980088B2 (ja) | 傷治癒を改善するプラスミノーゲン活性化因子からなる製剤の使用 | |
| Cooke et al. | PROTEOSE INTOXICATIONS AND INJURY OF BODY PROTEIN: IV. The Metabolism of Dogs with Sterile Abscess, Pancreatitis, and Pleuritis. | |
| US4871770A (en) | Method of inhibiting the activity of peroxidases and stimulating tumor growth | |
| JP2688603B2 (ja) | 血栓溶解剤 | |
| Huang-Lee et al. | Fibroblast contraction of collagen matrices with and without covalently bound hyaluronan | |
| Yarkoni et al. | Influence of oil concentration on the efficacy of tumor regression by emulsified components of mycobacteria |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MKEX | Expiry | ||
| MKEX | Expiry |
Effective date: 20020528 |